Phase 4Completed
C-Reactive Protein (CRP) in Obese Diabetic Women
Interventions Study for the Control of Diabetes Mellitus Type 2 in Obese Women
- Sponsor
- AstraZeneca (Industry)
- Enrollment
- 100 planned
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Rosuvastatin; improvement of lipid profile
- Ages
- adults, older adults
- Registry
- NCT00262548
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to determine whether treatment with rosuvastatin for 6 months in obese type 2 diabetic women will improve their lipid profiles and thus prevent the progression to cardiovascular disease.
Primary outcomes
- Patients will be receiving rosuvastatin/placebo for 6 months
- They will have baseline laboratory parameters taken such as glycemia
- HbA1c (glycosylated hemoglobin), low-density lipoprotein cholesterol (LDL-C), computed tomography (CT), high-density lipoprotein cholesterol (HDL-C), C-reactive protein (CRP), and retaken every 3 months
- Every month, patients will be evaluated at the clinic
History
Last registry update
Registered
Started